JP7692422B2 - 二重特異性抗ｐｄ－ｌ１／ｖｅｇｆ抗体及びその使用 - Google Patents

二重特異性抗ｐｄ－ｌ１／ｖｅｇｆ抗体及びその使用 Download PDF

Info

Publication number
JP7692422B2
JP7692422B2 JP2022544267A JP2022544267A JP7692422B2 JP 7692422 B2 JP7692422 B2 JP 7692422B2 JP 2022544267 A JP2022544267 A JP 2022544267A JP 2022544267 A JP2022544267 A JP 2022544267A JP 7692422 B2 JP7692422 B2 JP 7692422B2
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding
vegf
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022544267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511898A (ja
JP2023511898A5 (https=
Inventor
ワン，ヅオヅィー
チェン，ユンイン
リー，ドン
リー，ジン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Biologics Shanghai Co Ltd
Original Assignee
Wuxi Biologics Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics Shanghai Co Ltd filed Critical Wuxi Biologics Shanghai Co Ltd
Publication of JP2023511898A publication Critical patent/JP2023511898A/ja
Publication of JP2023511898A5 publication Critical patent/JP2023511898A5/ja
Application granted granted Critical
Publication of JP7692422B2 publication Critical patent/JP7692422B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022544267A 2020-01-21 2021-01-19 二重特異性抗ｐｄ－ｌ１／ｖｅｇｆ抗体及びその使用 Active JP7692422B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020073497 2020-01-21
CNPCT/CN2020/073497 2020-01-21
PCT/CN2021/072584 WO2021147829A1 (en) 2020-01-21 2021-01-19 A bispecific anti-pd-l1/vegf antibody and uses thereof

Publications (3)

Publication Number Publication Date
JP2023511898A JP2023511898A (ja) 2023-03-23
JP2023511898A5 JP2023511898A5 (https=) 2024-01-09
JP7692422B2 true JP7692422B2 (ja) 2025-06-13

Family

ID=76993149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022544267A Active JP7692422B2 (ja) 2020-01-21 2021-01-19 二重特異性抗ｐｄ－ｌ１／ｖｅｇｆ抗体及びその使用

Country Status (8)

Country Link
US (1) US20230242645A1 (https=)
EP (1) EP4093765A4 (https=)
JP (1) JP7692422B2 (https=)
AU (1) AU2021210025A1 (https=)
BR (1) BR112022014487A2 (https=)
CA (1) CA3165556A1 (https=)
WO (1) WO2021147829A1 (https=)
ZA (1) ZA202208337B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114106190B (zh) * 2020-08-31 2025-04-08 普米斯生物技术(珠海)有限公司 一种抗vegf/pd-l1双特异性抗体及其用途
CN114230669B (zh) * 2021-12-24 2024-01-30 天士力生物医药股份有限公司 一种双特异性抗体的生产方法
EP4543488A2 (en) * 2022-08-25 2025-04-30 Bright Biologics LLC Multispecific antibodies and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025257394A1 (en) * 2024-06-14 2025-12-18 BioNTech SE Combination therapy for cancer treatment
WO2025256761A1 (en) * 2024-06-14 2025-12-18 BioNTech SE Combination therapy for cancer treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018531039A (ja) 2015-07-31 2018-10-25 スジョウ・アルファマブ・カンパニー・リミテッドＳｕｚｈｏｕ Ａｌｐｈａｍａｂ Ｃｏ．，Ｌｔｄ． プログラム死リガンド（ｐｄｌ１）に対する単一ドメイン抗体およびその誘導体タンパク質
CN109053895A (zh) 2018-08-30 2018-12-21 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
CN109942712A (zh) 2019-04-01 2019-06-28 华博生物医药技术（上海）有限公司 抗pd-l1/vegf双功能抗体及其用途
JP2022550327A (ja) 2019-09-25 2022-12-01 ウーシー バイオロジクス アイルランド リミテッド 新規の抗ｐｄ－ｌ１抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
CN109575140B (zh) * 2017-09-29 2021-02-23 北京比洋生物技术有限公司 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
CA3090878A1 (en) * 2018-02-11 2019-08-15 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-1/anti-vegf natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
EP3758735B1 (en) * 2018-02-28 2023-12-13 AP Biosciences, Inc. Bifunctional proteins combining checkpoint blockade for targeted therapy
CN110305210B (zh) * 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
WO2019184909A1 (zh) * 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018531039A (ja) 2015-07-31 2018-10-25 スジョウ・アルファマブ・カンパニー・リミテッドＳｕｚｈｏｕ Ａｌｐｈａｍａｂ Ｃｏ．，Ｌｔｄ． プログラム死リガンド（ｐｄｌ１）に対する単一ドメイン抗体およびその誘導体タンパク質
CN109053895A (zh) 2018-08-30 2018-12-21 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
CN109942712A (zh) 2019-04-01 2019-06-28 华博生物医药技术（上海）有限公司 抗pd-l1/vegf双功能抗体及其用途
JP2022550327A (ja) 2019-09-25 2022-12-01 ウーシー バイオロジクス アイルランド リミテッド 新規の抗ｐｄ－ｌ１抗体

Also Published As

Publication number Publication date
AU2021210025A1 (en) 2022-08-25
WO2021147829A1 (en) 2021-07-29
CA3165556A1 (en) 2021-07-29
BR112022014487A2 (pt) 2022-09-27
US20230242645A1 (en) 2023-08-03
JP2023511898A (ja) 2023-03-23
ZA202208337B (en) 2024-01-31
EP4093765A1 (en) 2022-11-30
EP4093765A4 (en) 2023-06-28

Similar Documents

Publication Publication Date Title
JP7692422B2 (ja) 二重特異性抗ｐｄ－ｌ１／ｖｅｇｆ抗体及びその使用
TWI813934B (zh) 一種雙特異性抗pd-l1/vegf抗體及其用途
US12410250B2 (en) Anti-CD47 antibodies and uses thereof
US20220348664A1 (en) A novel anti-pd-l1/anti-lag-3 bispecific antibody and uses thereof
US20250313633A1 (en) Anti-B7H3 antibody and Uses thereof
US20250026833A1 (en) A bispecific anti-pd-l1/vegf antibody and uses thereof
TWI813951B (zh) 一種雙功能融合蛋白及其用途
US20210340252A1 (en) Anti-tim-3 antibodies and uses thereof
WO2024251160A1 (en) Anti-pvrig antibodies and uses thereof
WO2024251140A1 (en) Anti-tigit antibodies and uses thereof
WO2020119789A1 (en) Fully human antibodies against ox40, method for preparing the same, and use thereof
WO2020119793A1 (en) Humanized antibodies against ox40, method for preparing the same, and use thereof
JP2024500093A (ja) Ｐ－カドヘリンに対する抗体及びその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231225

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250603

R150 Certificate of patent or registration of utility model

Ref document number: 7692422

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150